NCT03211702 is a clinical trial in Lymphoma, Large B-cell, Diffuse, sponsored by Chonbuk National University Hospital.

Who is sponsoring NCT03211702?

NCT03211702 is sponsored by Chonbuk National University Hospital.

What condition does NCT03211702 study?

NCT03211702 studies Lymphoma, Large B-cell, Diffuse.

Is NCT03211702 still recruiting?

NCT03211702 is currently completed. Last updated 3 February 2023.

Last reviewed 2023-02-03 · How we verify

NCT03211702

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)

Completed Last updated 3 February 2023

What this trial tests

trial in Lymphoma, Large B-cell, Diffuse in 100 participants. Completed in 30 December 2020.

Timeline

25 August 2017

Primary endpoint
30 April 2018

30 December 2020

Quick facts

Lead sponsor	Chonbuk National University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	25 August 2017
Primary completion	30 April 2018
Estimated completion	30 December 2020
Sites	2 locations across South Korea

Conditions studied

Lymphoma, Large B-cell, Diffuse — all drugs for Lymphoma, Large B-cell, Diffuse →

Sponsor

Chonbuk National University Hospital

Who can join

65 and older, any sex, with Lymphoma, Large B-cell, Diffuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will validate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
Yhim HY, Park Y, Kim JA, Shin HJ, et al · · 2024 · cited 4× · PMID 38287501 · DOI 10.3904/kjim.2023.265

Verify or expand the search:

Other Chonbuk National University Hospital trials

Trials by the same sponsor.

NCT05324800 — the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement · NA · unknown
NCT05450939 — Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture · unknown
NCT05190237 — the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement. · NA · completed
NCT05495191 — Signal Intensity Gradient in Cerebral Arteries · completed
NCT04940910 — The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03211702 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonbuk National University Hospital
Last refreshed: 3 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03211702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing